WuXi Biologics (Cayman)

Growing Global Biopharma Demand Will Transform Outsourced Manufacturing

AnalystHighTarget

Not Invested

Consensus Narrative from 26 Analysts

Published

21 Jun 25

Updated

27 Aug 25

AnalystHighTarget's Fair Value

HK$45.49

31.8% undervalued

27 Aug

HK$31.04

188.5%

-0.9%

188.5%

-0.9%

Author's Valuation

HK$45.5

31.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

HK$45.5

31.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

13.25%

Life Sciences revenue growth rate

0.32%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.39%

Calculation

CN¥7.32b

Earnings '28

28.06x

PE Ratio '28

CN¥205.35b

Market Cap '28

CN¥205.35b

Market Cap '28

3.96b

No. shares '28

CN¥51.86

Share Price '28

CN¥51.86 Share Price '28

Discounted to 2025 @ 7.39% p.a.

CN¥41.87

Fair Value '25

CN¥41.87 Fair Value '25

Converted to HKD @ 1.0867 CNY/HKD Exchange Rate

HK$45.50

Fair Value '25